Navigation Links
Shire Reaches Agreement in Principle With U.S. Government
Date:2/1/2013

PHILADELPHIA, February 1, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that it has reached an agreement in principle to resolve the previously disclosed civil investigation into Shire's U.S. sales and marketing practices relating to ADDERALL XR®, VYVANSE® and DAYTRANA®[1].  

The investigation was led by the U.S. Attorney's Office for the Eastern District of Pennsylvania, and Shire disclosed the investigation in 2009.  The agreement also addresses sales and marketing practices relating to LIALDA® and PENTASA® pursuant to a subsequent voluntary disclosure made by Shire.  

Shire cooperated with the U.S. Government throughout the process that led to this agreement in principle.  Shire has recorded a $57.5M charge in the fourth quarter of 2012, comprised of the agreement in principle amount, interest and costs.  

The agreement in principle is subject to change until this matter is finally resolved.  Discussions between Shire and the U.S. Government are ongoing to establish a final resolution to the investigation.

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

  • Behavioral Health and Gastro Intestinal conditions
  • Rare Diseases
  • Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

--------------------------------------------------

1. DAYTRANA® is a trademark of Noven Pharmaceutical Inc.

We aspire to imagine and lead the future of healthcare, creating value for pa
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
2. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
3. Shire Changes its NASDAQ Ticker Symbol to SHPG
4. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
5. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
6. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
7. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
8. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
9. Mold from Sandy Remains a Problem in Rockaways; My Cleaning Products Reaches Out to Help with Its Green Mold Removal Spray
10. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
11. Cold Adds Up to Sandy Victims' Mold Problems; Optimal Chemical Reaches Out to Help by Advising the Use of Molderizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Stent retriever thrombectomy, an ... in the brain reduced disability after stroke, according ... MD, President of the Society of Vascular and ... a giant step forward that will change the ... patients," said Jovin, who is associate professor of ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... commercializing proven cancer therapies in new orphan drug ... 106th Annual Meeting of the American Association ... the potential for its lead product candidate ...
(Date:4/20/2015)... and Champaign, IL (PRWEB) April 20, 2015 ... the establishment of its 12th clinical research site: PMG ... Research has assumed operation of the clinical research department ... PMG’s footprint outside the Southeast to a second region ... a 150 multi-specialty physician practice enhances PMG’s access to ...
(Date:4/20/2015)... 20, 2015 Orthobiologics are substances ... injuries. The orthobiologics market is a rewarding market, which ... The global orthobiologics market report defines and segments the ... global orthobiologics market was valued at $5,712.4 million in ... 2019, at a CAGR of 6.7% from 2014 to ...
Breaking Biology Technology:SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) invites ... of the company,s 2008 investor meeting. The,corporate presentation ... Time on Thursday, March 13, 2008. The meeting ... of Jazz Pharmaceuticals, senior management team will provide ...
... Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") ... December 31, 2007., "2007 was our most ... the Company,s clinical trial program for REOLYSIN(R) with,Phase ... expanded and,initiated," said Dr. Brad Thompson, President and ...
... 6 Pathway Medical Technologies,which is developing innovative medical ... Buckman has been named as the new,Chairman of the ... been,acting Board Chairman since late 2006., "We are ... He brings,an extensive range of industry experience to the ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 3Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 4Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 5Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 6Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 7Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 8Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 9Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors 2
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... antitumor drug could, in theory, shorten patients, long-term survival, comes ... suggests a potentially better option. The study appears in the ... (online April 27). Many cancer treatments work ... growing tumors. Agents that block a vessel-promoting factor called VEGF ...
... Philip E. Bourne, a computational biologist and professor with ... with the 2009 Benjamin Franklin Award this week in ... the free and open dissemination of science and scientific ... April 28, at the annual meeting of the Bioinformatics ...
... international agencies, including the director of the U.S. ... of cooperation that could reduce the number of ... The agreement between the United States, Canada, Japan ... scientific recommendations on alternative toxicity testing methods that ...
Cached Biology News:A longer lasting tumor blocker 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 3Countries unite to reduce animal use in product toxicity testing worldwide 2Countries unite to reduce animal use in product toxicity testing worldwide 3
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Inquire...
... Isoaspartate Detection Kit is intended for quantitative ... and peptides, which can result from the ... of aspartic acid residues during storage or ... on the monitoring of charge differences for ...
...
Biology Products: